A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
Completed · Phase 2
Conditions studied: Type 2 Diabetes Mellitus, Chronic Kidney Disease
In brief
To assess the safety and efficacy of up to two REACT injections given 6 months (+4 weeks) apart and delivered into the biopsied kidney using a percutaneous approach in participants with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD).
Key facts
- Study ID
- NCT02836574
- Run by
- Prokidney
- People needed
- 83
- Starts
- 2016-09-01
- Expected to finish
- 2023-12-01
- Last updated by the study team
- 2025-08-24
Who can join
Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arizona — Tucson, Arizona, United States
- Kidney Associates of Colorado — Denver, Colorado, United States
- Yale Univeristy — New Haven, Connecticut, United States
- University of Florida — Gainesville, Florida, United States
- Boise Kidney and Hypertension Institute — Meridian, Idaho, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- University of Louisville — Louisville, Kentucky, United States
- Renal Associates of Baton Rouge — Baton Rouge, Louisiana, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Paragon Health — Kalamazoo, Michigan, United States
- Nephrology & Hypertension Associates — Tupelo, Mississippi, United States
- Mt. Sinai Hospital — New York, New York, United States
- University of North Carolina- Chapel Hill — Chapel Hill, North Carolina, United States
- Lehigh Valley Health Network — Allentown, Pennsylvania, United States
- Vanderbilt University — Nashville, Tennessee, United States
- University of Wisconsin-Madison — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.